Barings Global Short Duration High Yield Fund declares $0.1223 dividend

[ad_1] Juanmonino/E+ via Getty Images InflaRx (NASDAQ:IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients experiencing acute respiratory distress. The European Commission granted marketing authorization under exceptional circumstances for Gohibic, also known as vilobelimab, for the treatment of adult patients [ad_2]